Quantcast

Latest Vinorelbine Stories

2014-02-13 04:20:48

Pierre Fabre are thus reinforcing their oncology portfolio which already enjoys a combination of chemotherapies, monoclonal antibodies and immuno-conjugates assets at various development phases CASTRES, France and BANGALORE, India, February 13, 2014 /PRNewswire/ -- Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and...

2013-12-14 23:01:48

Scientists in Italy say vinorelbine may be a promising option for patients whose cancer returns after chemotherapy. Raleigh, NC (PRWEB) December 14, 2013 The anti-mitotic drug vinorelbine may be a safe and effective treatment for mesothelioma patients whose cancer progresses after first-line chemotherapy with the standard drugs. Pemetrexed (Alimta) is the primary first-line chemotherapy drug for mesothelioma patients with unresectable disease. The drug is usually paired with a...

2010-07-14 12:56:00

NEW YORK, July 14 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (ANX) announces the following Webcast: LHA Life Sciences & Med Tech Day 2010 What: Presentation When: July 20, 2010 @ 10:00 AM Eastern http://www.investorcalendar.com/ Where: ClientPage.asp?ID=160318 Live over the Internet --Simply log on to the How: web at the address above. Contact:...

2009-09-30 10:13:00

SCHAUMBURG, Ill., Sept. 30 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched vinorelbine injection, USP, an anti-mitotic chemotherapy drug. According to IMS, 2008 sales of vinorelbine injection, USP in the United States approximated $17 million. Sagent will begin marketing and shipping vinorelbine injection immediately. "Sagent has launched six products in the third quarter of 2009, including...

2009-02-10 08:00:00

SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext US: ANX) announced today that it has received written indications of interest from numerous companies representing a range of strategic transactions. The Company currently is evaluating all proposals and options. In December 2008, the Company announced that it was exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a...

2008-12-09 06:00:00

NUTLEY, N.J., Dec. 9 /PRNewswire/ -- Roche announced today that a total of 20 U.S. and global abstracts involving its oral chemotherapy Xeloda(R) (capecitabine) have been accepted for presentation at the 2008 San Antonio Breast Cancer Symposium (SABCS) in San AntonioDecember 12-14, including a late-breaking study in early breast cancer to be presented on Sunday, December 14, by the Finnish Breast Cancer Group. Two U.S. abstracts to be presented at the meeting compare the impact of...

2008-10-30 09:00:41

AMRI (NASDAQ: AMRI) reported data resulting from preclinical studies of ALB109564(a) at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held October 21-24 in Geneva, Switzerland. ALB109564(a) is a novel analog from an established and marketed class of tubulin inhibitors, which is designed to kill cancer cells by preventing cell mitosis. In preclinical testing, the compound was shown to demonstrate improved and potentially superior efficacy over existing members of...

2008-10-20 06:00:22

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. announced today that it has implemented a restructuring designed to reduce operating costs while continuing advancement towards the Company's near term goals. ADVENTRX will focus its resources solely on the continued development and regulatory approvals of ANX-530 (vinorelbine emulsion) and ANX- 514 (docetaxel emulsion). The restructuring reduced the Company's staff by a total of nine employees, or approximately...

2008-07-07 09:00:16

* Alocrest(tm) Phase 1 Data Demonstrates Potential for Improved Safety and Efficacy Compared to Conventional Vinorelbine * Menadione Topical Lotion Restores Kinase Activity and Does Not Inhibit the Anti-Tumor Effect of Erlotinib (Tarceva(r)) in Preclinical Models SOUTH SAN FRANCISCO, Calif., July 7, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, presented data for two of the...

2008-07-07 03:00:08

SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today announced the publication of results from its randomized phase III trial comparing OPAXIO(TM) (paclitaxel poliglumex, CT-2103) with gemcitabine or vinorelbine for the treatment of PS 2 (performance status 2) patients with previously untreated non-small cell lung cancer (NSCLC) in the Journal of Thoracic Oncology (Volume 3, Number 7, July 2008). Results showed that overall survival was similar...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related